(0.32%) 5 116.32 points
(0.31%) 38 357 points
(0.37%) 15 987 points
(-0.97%) $83.04
(5.36%) $2.03
(0.33%) $2 354.90
(0.56%) $27.69
(4.26%) $961.35
(-0.27%) $0.932
(-0.45%) $10.98
(-0.59%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States...
Stats | |
---|---|
本日の出来高 | 11 589.00 |
平均出来高 | 18 695.00 |
時価総額 | 36.64M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.59 |
ATR14 | $0.0570 (1.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-30 | Lurier Eliot M | Buy | 0 | |
2021-03-16 | Eansor Norman David | Buy | 14 285 | Common Stock |
2023-06-06 | Eansor Norman David | Buy | 8 000 | Stock Option (right to buy) |
2021-03-25 | Eansor Norman David | Buy | 7 142 | Common Stock |
2021-03-25 | Eansor Norman David | Sell | 14 285 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 66 397 235 | Sell: 1 245 536 |
Marker Therapeutics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Marker Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $3.31M |
総利益: | $-7.11M (-214.60 %) |
EPS: | $-1.930 |
FY | 2023 |
収益: | $3.31M |
総利益: | $-7.11M (-214.60 %) |
EPS: | $-1.930 |
FY | 2022 |
収益: | $9.00M |
総利益: | $5.32M (59.13 %) |
EPS: | $-3.58 |
FY | 2021 |
収益: | $1 242.00 |
総利益: | $1 241.71 (100.00 %) |
EPS: | $-8.90 |
Financial Reports:
No articles found.
Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。